RedShiftBio

The decision makers in RedShiftBio are Alan Opper, Dennis Merrill, Jinhong Kim, etc. Click to Find RedShiftBio decision makers emails.

Microfluidic Modulation Spectroscopy (MMS) is a proprietary technology developed by RedShiftBio that enhances the structural characterization of biomolecules. By utilizing microfluidic systems, MMS allows for precise control over the sample environment and enables the collection of high-resolution spectral data. This technology benefits biomolecular characterization by providing detailed insights into molecular interactions, stability, and conformational changes, which are critical for drug discovery and development.

RedShiftBio's platform is designed to analyze a wide range of biomolecules, including proteins, antibodies, and other biologics. Our technology is particularly effective for studying complex biomolecular structures, such as those found in biotherapeutics and biosimilars. This versatility allows researchers to gain insights into the stability, aggregation, and overall behavior of various biomolecular candidates throughout the development process.

RedShiftBio supports the drug discovery process by providing advanced biophysical characterization services that help researchers understand the structural properties and stability of drug candidates. Our proprietary MMS technology, along with other analytical techniques such as Circular Dichroism (CD-UV) and Differential Scanning Calorimetry (DSC), enables the identification of critical quality attributes and potential issues early in the development process, ultimately accelerating the path to successful drug approval.

RedShiftBio serves a variety of industries within the life sciences sector, including pharmaceuticals, biotechnology, and biomanufacturing. Our solutions are particularly relevant for companies involved in drug development, formulation, and the production of biologics. By providing advanced analytical tools and expertise, we help organizations in these industries ensure the quality and efficacy of their biomolecular products.

Yes, RedShiftBio has extensive experience in supporting the development of biosimilars. Our advanced characterization techniques, including MMS and high-performance liquid chromatography (HPLC-SEC), allow for comprehensive analysis of the structural and functional similarities between biosimilars and their reference biologics. This is crucial for demonstrating biosimilarity and ensuring regulatory compliance throughout the development process.

RedShiftBio offers comprehensive support for process development, including analytical method development and validation, stability studies, and characterization of intermediates and final products. Our team of experts utilizes cutting-edge technologies to optimize processes, identify potential issues, and ensure that products meet the required quality standards. This support is essential for companies looking to streamline their development processes and enhance the efficiency of their operations.